Trailing TRAIL resistance: Novel targets for TRAIL sensitization in cancer cells

Frontiers in Oncology

Volumn 5, Issue APR, 2015, Pages

  Trivedi, Rachana ^a   Mishra, Durga Prasad ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Apoptosis; Cancer; DR4; DR5; TRAIL; TRAIL resistance

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CASPASE 10; CASPASE 3; CASPASE 8; CISPLATIN; DEATH RECEPTOR; GEMCITABINE; HEAT SHOCK PROTEIN; INITIATION FACTOR 4E; MAPATUMUMAB; MESSENGER RNA; PACLITAXEL; PROTEASOME; PROTEIN BAK; PROTEIN BAX; PROTEIN KINASE B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CANCER CELL; CELL HETEROGENEITY; DRUG RESISTANCE; DRUG SENSITIZATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION AND TRANSLATION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; METASTASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 84934278552     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00069     Document Type: Review

References (213)

1. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis (2001) 6(3):191-7. doi:10.1023/A:1011336726649
2. Hall MA, Cleveland JL. Clearing the TRAIL for cancer therapy. Cancer Cell (2007) 12(1):4-6. doi:10.1016/j.ccr.2007.06.011
3. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science (1998) 281(5381):1305-8. doi:10.1126/science.281.5381.1305
4. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 26(25):3745-57. doi:10.1038/sj.onc.1210374
5. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 271(22):12687-90. doi:10.1074/jbc.271.22.12687
6. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 5(2):157-63. doi:10.1038/5517
7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 104(2):155-62.
8. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 3(6):673-82. doi:10.1016/1074-7613(95)90057-8
9. Fulda S. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Adv Exp Med Biol (2014) 818:167-80. doi:10.1007/978-1-4471-6458-6_8
10. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 11(10):1299-314. doi:10.1517/14728222.11.10.1299
11. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 187(8):1205-13. doi:10.1084/jem.187.8.1205
12. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol (1997) 99(3):618-24. doi:10.1046/j.1365-2141.1997.4393250.x
13. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM. JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. Int J Cancer (1999) 80(3):417-24. doi:10.1002/(SICI)1097-0215(19990129)80:3%3C417::AID-IJC14%3E3.0.CO;2-B
14. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol (1998) 28(1):143-52. doi:10.1002/(SICI)1521-4141(199801)28:01%3C143::AID-IMMU143%3E3.0.CO;2-3
15. Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol (2004) 172(1):123-9. doi:10.4049/jimmunol.172.1.123
16. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature (2005) 434(7029):88-93. doi:10.1038/nature03337
17. Mariani SM, Krammer PH. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol (1998) 28(5):1492-8. doi:10.1002/(SICI)1521-4141(199805)28:05%3C1492::AID-IMMU1492%3E3.0.CO;2-X
18. Monleon I, Martinez-Lorenzo MJ, Monteagudo L, Lasierra P, Taules M, Iturralde M, et al. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol (2001) 167(12):6736-44. doi:10.4049/jimmunol.167.12.6736
19. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 277(5327):815-8. doi:10.1126/science.277.5327.815
20. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 277(5327):818-21. doi:10.1126/science.277.5327.818
21. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J (1997) 16(17):5386-97. doi:10.1093/emboj/16.17.5386
22. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 7(12):1003-6. doi:10.1016/S0960-9822(06)00422-2
23. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 7(6):813-20. doi:10.1016/S1074-7613(00)80399-4
24. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 273(23):14363-7. doi:10.1074/jbc.273.23.14363
25. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol (2007) 39(7-8):1462-75. doi:10.1016/j.biocel.2007.02.007
26. Corazza N, Kassahn D, Jakob S, Badmann A, Brunner T. TRAIL-induced apoptosis: between tumor therapy and immunopathology. Ann N Y Acad Sci (2009) 1171:50-8. doi:10.1111/j.1749-6632.2009.04905.x
27. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene (2000) 19(14):1735-43. doi:10.1038/sj.onc.1203489
28. Fulda S. The dark side of TRAIL signaling. Cell Death Differ (2013) 20(7):845-6. doi:10.1038/cdd.2013.36
29. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2013) 29(34):4752-65. doi:10.1038/onc.2010.221
30. Picarda G, Trichet V, Teletchea S, Heymann D, Redini F. TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res (2012) 2(1):45-64.
31. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 13(9):1070-7. doi:10.1038/nm1627
32. Held J, Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat (2001) 4(4):243-52. doi:10.1054/drup.2001.0208
33. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene (2008) 27(48):6207-15. doi:10.1038/onc.2008.298
34. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer (2002) 2(4):277-88. doi:10.1038/nrc776
35. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 12(6):611-20. doi:10.1016/S1074-7613(00)80212-5
36. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell (1998) 94(4):491-501. doi:10.1016/S0092-8674(00)81590-1
37. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell (1998) 94(4):481-90. doi:10.1016/S0092-8674(00)81589-5
38. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 102(1):33-42. doi:10.1016/S0092-8674(00)00008-8
39. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem (2005) 280(15):14507-13. doi:10.1074/jbc.M414425200
40. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 625(1-3):63-72. doi:10.1016/j.ejphar.2009.06.066
41. Dickens LS, Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L, et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell (2012) 47(2):291-305. doi:10.1016/j.molcel.2012.05.004
42. Safa AR, Pollok KE. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel) (2011) 3(2):1639-71. doi:10.3390/cancers3021639
43. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol (2010) 42(2):210-3. doi:10.1016/j.biocel.2009.11.015
44. Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol (2012) 34(3):176-84.
45. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 124(3):601-13. doi:10.1016/j.cell.2006.01.021
46. Pawar PS, Micoli KJ, Ding H, Cook WJ, Kappes JC, Chen Y, et al. Calmodulin binding to cellular FLICE-like inhibitory protein modulates Fas-induced signalling. Biochem J (2008) 412(3):459-68. doi:10.1042/BJ20071507
47. McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scarpelli M, Salto-Tellez M, et al. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res (2012) 18(14):3822-33. doi:10.1158/1078-0432.CCR-11-3277
48. Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G, et al. c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3beta activity. Cell Death Differ (2010) 17(12):1908-16. doi:10.1038/cdd.2010.65
49. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature (2009) 459(7245):428-32. doi:10.1038/nature08012
50. Scheper GC, van der Knaap MS, Proud CG. Translation matters: protein synthesis defects in inherited disease. Nat Rev Genet (2007) 8(9):711-23. doi:10.1038/nrg2142
51. Kozak M. Emerging links between initiation of translation and human diseases. Mamm Genome (2002) 13(8):401-10. doi:10.1007/s00335-002-4002-5
52. Barnhart BC, Simon MC. Taking aim at translation for tumor therapy. J Clin Invest (2007) 117(9):2385-8. doi:10.1172/JCI33107
53. von der Haar T, Gross JD, Wagner G, McCarthy JE. The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat Struct Mol Biol (2004) 11(6):503-11. doi:10.1038/nsmb779
54. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 433(7025):477-80. doi:10.1038/nature03205
55. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res (2008) 68(3):631-4. doi:10.1158/0008-5472.CAN-07-5635
56. Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia (2010) 12(4):346-56. doi:10.1593/neo.10144
57. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood (2001) 98(9):2603-14. doi:10.1182/blood.V98.9.2603
58. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res (2004) 64(20):7570-8. doi:10.1158/0008-5472.CAN-04-1238
59. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov (2008) 7(12):1013-30. doi:10.1038/nrd2755
60. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep (2006) 7(9):880-5. doi:10.1038/sj.embor.7400779
61. Soboloff J, Berger SA. Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. J Biol Chem (2002) 277(16):13812-20. doi:10.1074/jbc.M112129200
62. Oslowski CM, Urano F. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol (2011) 490:71-92. doi:10.1016/B978-0-12-385114-7.00004-0
63. Masud A, Mohapatra A, Lakhani SA, Ferrandino A, Hakem R, Flavell RA. Endoplasmic reticulum stress-induced death of mouse embryonic fibroblasts requires the intrinsic pathway of apoptosis. J Biol Chem (2007) 282(19):14132-9. doi:10.1074/jbc.M700077200
64. He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, et al. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene (2002) 21(17):2623-33. doi:10.1038/sj.onc.1205345
65. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res (2005) 65(14):6364-70. doi:10.1158/0008-5472.CAN-05-0312
66. Liu H, Jiang CC, Lavis CJ, Croft A, Dong L, Tseng HY, et al. 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Mol Cancer (2009) 8:122. doi:10.1186/1476-4598-8-122
67. Teng Y, Gao M, Wang J, Kong Q, Hua H, Luo T, et al. Inhibition of eIF2alpha dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells. Cell Death Dis (2014) 5:e1060. doi:10.1038/cddis.2014.24
68. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell (2009) 138(2):377-88. doi:10.1016/j.cell.2009.05.022
69. Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S. 3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis (2006) 27(4):717-28. doi:10.1093/carcin/bgi270
70. Martin-Perez R, Niwa M, Lopez-Rivas A. ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis (2012) 17(4):349-63. doi:10.1007/s10495-011-0673-2
71. Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K. Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One (2010) 5(7):e11865. doi:10.1371/journal.pone.0011865
72. Murai M, Inoue T, Suzuki-Karasaki M, Ochiai T, Ra C, Nishida S, et al. Diallyl trisulfide sensitizes human melanoma cells to TRAIL-induced cell death by promoting endoplasmic reticulum-mediated apoptosis. Int J Oncol (2012) 41(6):2029-37. doi:10.3892/ijo.2012.1656
73. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene (2004) 23(11):2009-15. doi:10.1038/sj.onc.1207373
74. Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol (2002) 3(2):112-21. doi:10.1038/nrm731
75. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer (2004) 4(5):349-60. doi:10.1371/journal.pone.0084248
76. Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E, et al. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol (2003) 23(3):777-90. doi:10.1128/MCB.23.3.777-790.2003
77. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene (2003) 22(32):4953-63. doi:10.1038/sj.onc.1206656
78. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene (2004) 23(14):2554-8. doi:10.1038/sj.onc.1207351
79. Conticello C, Adamo L, Vicari L, Giuffrida R, Iannolo G, Anastasi G, et al. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Acta Haematol (2008) 120(1):19-30. doi:10.1159/000151511
80. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther (2007) 6(7):2103-12. doi:10.1158/1535-7163.MCT-07-0167
81. Sarhan D, Wennerberg E, D'Arcy P, Gurajada D, Linder S, Lundqvist A. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. Cancer Immunol Immunother (2013) 62(8):1359-68. doi:10.1007/s00262-013-1439-1
82. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol (2008) 180(9):6199-210. doi:10.4049/jimmunol.180.9.6199
83. Inoue T, Shiraki K, Fuke H, Yamanaka Y, Miyashita K, Yamaguchi Y, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs (2006) 17(3):261-8. doi:10.1097/00001813-200603000-00004
84. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 21(9):1350-64. doi:10.1038/cdd.2014.81
85. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature (1996) 379(6563):349-53. doi:10.1038/379349a0
86. Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res (2000) 10(3):169-77. doi:10.1038/sj.cr.7290046
87. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci U S A (2001) 98(15):8662-7. doi:10.1073/pnas.161506698
88. Yuan BZ, Chapman J, Ding M, Wang J, Jiang B, Rojanasakul Y, et al. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages. BMC Cancer (2013) 13:140. doi:10.1186/1471-2407-13-140
89. Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, et al. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. Cell Death Dis (2014) 5:e1489. doi:10.1038/cddis.2014.455
90. Schlegel CR, Fonseca AV, Stocker S, Georgiou ML, Misterek MB, Munro CE, et al. DAPK2 is a novel modulator of TRAIL-induced apoptosis. Cell Death Differ (2014) 21(11):1780-91. doi:10.1038/cdd.2014.93
91. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science (2002) 295(5561):1852-8. doi:10.1126/science.1068408
92. Morimoto RI, Kline MP, Bimston DN, Cotto JJ. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem (1997) 32:17-29.
93. Panner A, Murray JC, Berger MS, Pieper RO. Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res (2007) 67(19):9482-9. doi:10.1158/0008-5472.CAN-07-0569
94. Gething MJ, Sambrook J. Protein folding in the cell. Nature (1992) 355(6355):33-45. doi:10.1038/355033a0
95. Hightower LE. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell (1991) 66(2):191-7. doi:10.1016/0092-8674(91)90611-2
96. Paolini M, Mesirca R, Pozzetti L, Gialluca N, Bauer C, Biagi GL, et al. Cancer chemoprevention: some complications and limitations. Cancer Detect Prev (1998) 22(1):68-74. doi:10.1046/j.1525-1500.1998.00088.x
97. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) (2003) 228(2):111-33.
98. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A (1996) 93(16):8379-83. doi:10.1073/pnas.93.16.8379
99. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol (2000) 2(8):469-75. doi:10.1038/35019501
100. Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, Kumar V, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J (2000) 19(16):4310-22. doi:10.1093/emboj/19.16.4310
101. Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S. Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. EMBO J (1999) 18(8):2040-8. doi:10.1093/emboj/18.8.2040
102. Lu X, Xiao L, Wang L, Ruden DM. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem Pharmacol (2012) 83(8):995-1004. doi:10.1016/j.bcp.2011.11.011
103. Williams CR, Tabios R, Linehan WM, Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol (2007) 178(4 Pt 1):1528-32. doi:10.1016/j.juro.2007.05.120
104. Ma Y, Lakshmikanthan V, Lewis RW, Kumar MV. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol Cancer Ther (2006) 5(1):170-8. doi:10.1158/1535-7163.MCT-05-0129
105. Vasilevskaya IA, O'Dwyer PJ. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol (2005) 70(4):580-9. doi:10.1016/j.bcp.2005.05.018
106. Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res (2006) 12(2):584-90. doi:10.1158/1078-0432.CCR-05-1194
107. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 4:e838. doi:10.1038/cddis.2013.350
108. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther (2011) 10(9):1533-41. doi:10.1158/1535-7163.MCT-11-0047
109. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta (2009) 1805(1):53-71. doi:10.1016/j.bbcan.2009.08.003
110. Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Enhancement of tumor-TRAIL susceptibility by modulation of autophagy. Autophagy (2008) 4(7):940-3. doi:10.4161/auto.6769
111. Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S, et al. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol (2009) 93(3):303-18. doi:10.1007/s11060-008-9788-x
112. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 5(9):769-84. doi:10.1038/nrd2133
113. Esteller M. Epigenetics in cancer. N Engl J Med (2008) 358(11):1148-59. doi:10.1056/NEJMra072067
114. Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T, et al. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res (2003) 9(17):6401-9.
115. Zuzak TJ, Steinhoff DF, Sutton LN, Phillips PC, Eggert A, Grotzer MA. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur J Cancer (2002) 38(1):83-91. doi:10.1016/S0959-8049(01)00355-0
116. Riffkin CD, Gray AZ, Hawkins CJ, Chow CW, Ashley DM. Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. Neuro Oncol (2001) 3(4):229-40. doi:10.1215/15228517-3-4-229
117. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther (2005) 4(2):139-63. doi:10.4161/cbt.4.2.1508
118. Moon DO, Asami Y, Long H, Jang JH, Bae EY, Kim BY, et al. Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2alpha/CHOP-dependent manner. Toxicol In vitro (2013) 27(1):257-63. doi:10.1016/j.tiv.2012.09.001
119. Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA, Lim JH, et al. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis (2013) 34(8):1918-28. doi:10.1093/carcin/bgt137
120. Trivedi R, Maurya R, Mishra DP. Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. Cell Death Dis (2014) 5:e1465. doi:10.1038/cddis.2014.429
121. He L, Jang JH, Choi HG, Lee SM, Nan MH, Jeong SJ, et al. Oligomycin A enhances apoptotic effect of TRAIL through CHOP-mediated death receptor 5 expression. Mol Carcinog (2013) 52(2):85-93. doi:10.1002/mc.21831
122. Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, et al. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res (2007) 67(12):5880-8. doi:10.1158/0008-5472.CAN-07-0213
123. Su RY, Chi KH, Huang DY, Tai MH, Lin WW. 15-deoxy-Delta12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol Cancer Ther (2008) 7(10):3429-40. doi:10.1158/1535-7163.MCT-08-0498
124. Prasad S, Yadav VR, Ravindran J, Aggarwal BB. ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res (2011) 71(2):538-49. doi:10.1158/0008-5472.CAN-10-3121
125. Yang JF, Cao JG, Tian L, Liu F. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells. Cancer Chemother Pharmacol (2012) 69(1):195-206. doi:10.1007/s00280-011-1686-9
126. Kim YJ, Choi WI, Ko H, So Y, Kang KS, Kim I, et al. Neobavaisoflavone sensitizes apoptosis via the inhibition of metastasis in TRAIL-resistant human glioma U373MG cells. Life Sci (2014) 95(2):101-7. doi:10.1016/j.lfs.2013.10.035
127. Kim HB, Kim MJ, Kim DY, Lee JW, Bae JH, Kim DW, et al. High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde. Mol Cancer (2011) 10:46. doi:10.1186/1476-4598-10-46
128. Sung ES, Park KJ, Choi HJ, Kim CH, Kim YS. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res (2012) 318(13):1564-76. doi:10.1016/j.yexcr.2012.04.003
129. Koschny R, Boehm C, Sprick MR, Haas TL, Holland H, Xu LX, et al. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex. J Neuropathol Exp Neurol (2014) 73(11):1034-46. doi:10.1097/NEN.0000000000000129
130. Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res (2010) 8(5):729-38. doi:10.1158/1541-7786.MCR-10-0022
131. Seol DW. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun (2011) 416(1-2):222-5. doi:10.1016/j.bbrc.2011.11.053
132. Kahana S, Finniss S, Cazacu S, Xiang C, Lee HK, Brodie S, et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal (2011) 23(8):1348-57. doi:10.1016/j.cellsig.2011.03.017
133. Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther (2011) 10(1):198-208. doi:10.1158/1535-7163.MCT-10-0725
134. Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, et al. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther (2010) 9(6):1842-51. doi:10.1158/1535-7163.MCT-09-0918
135. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther (2008) 7(5):1091-100. doi:10.1158/1535-7163.MCT-07-2368
136. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, et al. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood (2008) 111(5):2797-805. doi:10.1182/blood-2007-08-110445
137. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab (2007) 92(5):1938-42. doi:10.1210/jc.2006-2157
138. Siegelin MD, Habel A, Gaiser T. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol Dis (2009) 33(2):243-9. doi:10.1016/j.nbd.2008.10.005
139. Mellier G, Liu D, Bellot G, Holme AL, Pervaiz S. Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27. Cell Death Dis (2013) 4:e890. doi:10.1038/cddis.2013.413
140. Monma H, Harashima N, Inao T, Okano S, Tajima Y, Harada M. The HSP70 and autophagy inhibitor pifithrin-mu enhances the antitumor effects of TRAIL on human pancreatic cancer. Mol Cancer Ther (2013) 12(4):341-51. doi:10.1158/1535-7163.MCT-12-0954
141. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene (2005) 24(29):4609-23. doi:10.1038/sj.onc.1208585
142. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ (2004) 11(Suppl 2):S193-206. doi:10.1038/sj.cdd.4401535
143. Muhlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer (2006) 6:214. doi:10.1186/1471-2407-6-214
144. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene (2004) 23(37):6261-71. doi:10.1038/sj.onc.1207830
145. D'Acunto CW, Carratu A, Rodriquez M, Taddei M, Parente L, Petrella A. LGP1, A histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis. Anticancer Res (2010) 30(3):887-94.
146. Kim HB, Kim MJ, Lee SH, Lee JW, Bae JH, Kim DW, et al. Amurensin G, a novel SIRT1 inhibitor, sensitizes TRAIL-resistant human leukemic K562 cells to TRAIL-induced apoptosis. Biochem Pharmacol (2012) 84(3):402-10. doi:10.1016/j.bcp.2012.03.014
147. Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis (2011) 32(10):1450-8. doi:10.1093/carcin/bgr135
148. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, et al. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res (2005) 65(24):11469-77. doi:10.1158/0008-5472.CAN-05-1724
149. Fulda S, Debatin KM. 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene (2006) 25(37):5125-33. doi:10.1038/sj.onc.1209518
150. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene (2001) 20(41):5865-77. doi:10.1038/sj.onc.1204750
151. Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C, et al. Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene (2010) 29(11):1641-52. doi:10.1038/onc.2009.448
152. Taniguchi H, Horinaka M, Yoshida T, Yano K, Goda AE, Yasuda S, et al. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules. Mol Cancer Ther (2012) 11(10):2294-300. doi:10.1158/1535-7163.MCT-12-0031
153. Goda AE, Yoshida T, Horinaka M, Yasuda T, Shiraishi T, Wakada M, et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene (2008) 27(24):3435-45. doi:10.1038/sj.onc.1211008
154. Azijli K, van Roosmalen IA, Smit J, Pillai S, Fukushima M, de Jong S, et al. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells. Cancer Chemother Pharmacol (2014) 73(6):1273-83. doi:10.1007/s00280-014-2465-1
155. He T, Haapa-Paananen S, Kaminskyy VO, Kohonen P, Fey V, Zhivotovsky B, et al. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis. Oncogene (2014) 33(27):3538-49. doi:10.1038/onc.2013.313
156. Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B, Meyn RE. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem (2003) 278(23):20593-602. doi:10.1074/jbc.M211010200
157. Hernandez A, Wang QD, Schwartz SA, Evers BM. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg (2001) 5(1):56-65. doi:10.1016/S1091-255X(01)80014-7
158. Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodovar C, Palacios C, Lopez-Rivas A. Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem (2003) 278(15):12759-68. doi:10.1074/jbc.M212392200
159. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324(5930):1029-33. doi:10.1126/science.1160809
160. Dang CV. Links between metabolism and cancer. Genes Dev (2012) 26(9):877-90. doi:10.1101/gad.189365.112
161. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 65(2):613-21.
162. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature (2009) 457(7225):51-6. doi:10.1038/nature07618
163. Boada J, Roig T, Perez X, Gamez A, Bartrons R, Cascante M, et al. Cells overexpressing fructose-2,6-bisphosphatase showed enhanced pentose phosphate pathway flux and resistance to oxidative stress. FEBS Lett (2000) 480(2-3):261-4. doi:10.1016/S0014-5793(00)01950-5
164. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 4(11):891-9. doi:10.1038/nrc1478
165. Zhong D, Liu X, Schafer-Hales K, Marcus AI, Khuri FR, Sun SY, et al. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther (2008) 7(4):809-17. doi:10.1158/1535-7163.MCT-07-0559
166. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol (2004) 53(2):116-22. doi:10.1007/s00280-003-0724-7
167. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell (2007) 11(1):37-51. doi:10.1016/j.ccr.2006.10.020
168. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat (2010) 120(1):253-60. doi:10.1007/s10549-009-0435-9
169. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis (2013) 4:e532. doi:10.1038/cddis.2013.60
170. Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL, et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci (2010) 101(6):1447-53. doi:10.1111/j.1349-7006.2010.01562.x
171. Nam SY, Amoscato AA, Lee YJ. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene (2002) 21(3):337-46. doi:10.1038/sj.onc.1205068
172. Kaelin WG Jr, Thompson CB. Q&A: cancer: clues from cell metabolism. Nature (2010) 465(7298):562-4. doi:10.1038/465562a
173. Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget (2010) 1(8):734-40.
174. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell (2004) 5(4):341-51. doi:10.1016/S1535-6108(04)00080-7
175. Khutornenko AA, Roudko VV, Chernyak BV, Vartapetian AB, Chumakov PM, Evstafieva AG. Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc Natl Acad Sci U S A (2010) 107(29):12828-33. doi:10.1073/pnas.0910885107
176. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 12(8):895-904. doi:10.1038/nm1469
177. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol (2008) 5(4):206-19. doi:10.1038/ncponc1066
178. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther (2010) 9(12):3254-66. doi:10.1158/1535-7163.MCT-10-0582
179. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 27(20):2192-206. doi:10.1101/gad.225334.113
180. Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis (2007) 24(8):587-97. doi:10.1007/s10585-007-9114-6
181. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T, et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene (2003) 22(46):7155-69. doi:10.1038/sj.onc.1206887
182. Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM. Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem (2008) 318(1-2):89-99. doi:10.1007/s11010-008-9860-z
183. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res (2008) 68(2):537-44. doi:10.1158/0008-5472.CAN-07-5682
184. Wang H, Xu C, Kong X, Li X, Wang Y, Ding X, et al. Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One (2014) 9(6):e99067. doi:10.1371/journal.pone.0099067
185. Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, et al. Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death Dis (2014) 5:e1434. doi:10.1038/cddis.2014.410
186. Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM, et al. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene (2003) 22(51):8356-69. doi:10.1038/sj.onc.1207004
187. Mouzakiti A, Packham G. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol (2003) 122(1):61-9. doi:10.1046/j.1365-2141.2003.04424.x
188. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials (2009) 4(1):34-41. doi:10.2174/157488709787047530
189. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 28(17):2839-46. doi:10.1200/JCO.2009.25.1991
190. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev (2003) 14(3-4):337-48. doi:10.1016/S1359-6101(03)00029-7
191. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res (2004) 64(23):8502-6. doi:10.1158/0008-5472.CAN-04-2599
192. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol (2008) 19(6):1060-7. doi:10.1093/annonc/mdn015
193. Buchsbaum DJ, Zhou T, Lobuglio AF. TRAIL receptor-targeted therapy. Future Oncol (2006) 2(4):493-508. doi:10.2217/14796694.2.4.493
194. Carlo-Stella C, Lavazza C, Locatelli A, Vigano L, Gianni AM, Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res (2007) 13(8):2313-7. doi:10.1158/1078-0432.CCR-06-2774
195. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med (2000) 6(5):564-7. doi:10.1038/75045
196. Qin J, Chaturvedi V, Bonish B, Nickoloff BJ. Avoiding premature apoptosis of normal epidermal cells. Nat Med (2001) 7(4):385-6. doi:10.1038/86401
197. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 7(4):383-5. doi:10.1038/nm1201-1291
198. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol (2008) 26(21):3621-30. doi:10.1200/JCO.2007.15.7198
199. Stieglmaier J, Bremer E, Kellner C, Liebig TM, Ten Cate B, Peipp M, et al. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother (2008) 57(2):233-46. doi:10.1007/s00262-007-0370-8
200. Bremer E, van Dam GM, de Bruyn M, van Riezen M, Dijkstra M, Kamps G, et al. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol Ther (2008) 16(12):1919-26. doi:10.1038/mt.2008.203
201. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2005) 280(3):2205-12. doi:10.1074/jbc.M410660200
202. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A (2006) 103(23):8634-9. doi:10.1073/pnas.0510187103
203. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol (1999) 162(5):2597-605.
204. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 7(8):954-60. doi:10.1038/91000
205. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res (2007) 13(20):6187-94. doi:10.1158/1078-0432.CCR-07-0950
206. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev (2008) 19(3-4):325-31. doi:10.1016/j.cytogfr.2008.04.001
207. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res (2005) 65(24):11265-70. doi:10.1158/0008-5472.CAN-05-2801
208. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol (2001) 166(8):4891-8. doi:10.4049/jimmunol.166.8.4891
209. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res (2009) 15(17):5584-90. doi:10.1158/1078-0432.CCR-09-0996
210. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res (2001) 61(19):7339-48.
211. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA. Human agonistic TRAIL receptor antibodies mapatumumab and lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer (2007) 6:66. doi:10.1186/1476-4598-6-66
212. Amelio I, Gostev M, Knight RA, Willis AE, Melino G, Antonov AV. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis (2014) 5:e1051. doi:10.1038/cddis.2014.9
213. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res (1999) 59(3):734-41.